CHEK1 and rectal cancer: CHIR-124 has been shown to synergize with gemcitabine in pancreatic cell culture,94 and an alternate Chk1 inhibitor, SRA737, is being tested in Phase I/II clinical trials in combination with gemcitabine in anogenital cancer, cervical cancer, ovarian cancer, rectal cancer, and non-small cell lung cancer.95